Baltic Countries

ScanBalt celebrates its 10th anniversary

17.08.2011

Under the motto “10 Years ScanBalt Bioregion – Towards a Balanced Regional Development and Smart Specialisation in the Baltic Sea Region”, the ScanBalt Bio­Region is holding the 10th ScanBalt Forum from September 21st-23rd. Launched in 2001, ScanBalt has become the most significant cooperation network for the life sciences and health sector in Northern Europe. The cross-border initiative that is headquartered in Copenhagen encompasses a region of 85 million inhabitants, 60 universities, 248 hospitals and about 2,500 life science and biotech com­panies – around 700 of which are SMEs.

The key issue for ScanBalt is to bundle the interests of its 67 members in the Baltic Sea Region, as well as North-West Russia, Norway and the Northern Netherlands. And the network is accomplishing that task with increasing success. So far, 15 international projects for companies, universities, and research facilities have been initiated and supported under the ScanBalt umbrella, all of them aimed at developing the areas bordering the Baltic Sea into a globally competitive meta-region. Taking yearly turns, members rotate duties in the ScanBalt Forum in order to strengthen cross-border cooperation within the ScanBalt Bio region. Following the founding session at the first Baltic Biotech Forum, which took place in Teschow in the German State of Mecklenburg-Vorpommern in 2001, the event has migrated almost completely around the Baltic Sea region from Oslo to Tallinn. The meeting in Heringsdorf on the German/Polish island of Usedom marks the return of ScanBalt to the southernmost areas of the initiative.

Flagship for Europe:

the Baltic Sea Health Region

The agenda of this year’s Forum is filled with topics like the EU flagship “Baltic Sea Health Region” project, the “Green Valley”project with environmental projects and activities in the region, and the opportunities and challenges of cross-border cooperation in the Baltic Sea Region. Contributors to the 2010 ScanBalt Forum in Tallin (Estonia) successfully managed to incorporate the “ScanBalt Health Region” project as a keystone in the EU Baltic Sea Strategy, and added proposals to the emerging 8th EU Research Framework Programme, which includes a “Master Plan on Health“ for the Baltic Sea region.
Successes like these have encouraged the 2011 Forum organisers. ScanBalt chairman Wolfgang Blank has high expectations: “The ScanBalt BioRegion has emerged as a model region for Europe in the cooperation between business, universities, and the public sector. In future, we need to keep working to improve the mobility of people, know­ledge, and ideas within Europe, and to reduce regional inequalities. In Heringsdorf, we are attempting to pave the way for well-balanced regional development.”

Cross-border success

Lectures and workshops are one way to present new projects from areas that include ­regenerative medicine, marine and industrial biotechnology, the fight against multi-resistant bacteria, identifying and defining new areas of cooperation, developing expansion strategies in the life sciences and health economy fields, and for mobilising resources for implementation. 250 participants from business, science, and the public sector are expected at the Forum, which falls under the patronage of Mecklenburg-Vorpommern, currently led by state premiere Erwin Sellering. Anyone interested is welcome to attend (registration at: www.scanbaltforum2011.eu).
The ScanBalt Forum is organised by the West Pomeranian Medical University Szczecin/Poland, the University of Klaipeda/Lithuania and as part of the project Eco4­Life, which is partly financed by the EU (European Regional Development Fund). The lead partner is BioCon Valley® GmbH, a central contact and service provider for life sciences, biotechnology and the bio­sciences in Mecklenburg-Vorpommern.

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1983

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/scanbalt-celebrates-its-10th-anniversary.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014


Current issue

All issues

Product of the week

Products